UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026 Trial costs funded by United Kingdom government and leading motor neuron disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results